Skip to main content

The Globe and Mail

Quebec’s plan to nurse Montreal’s battered pharmaceutical sector back to health

Philippe Walker lost his job last February. Worse, the molecular biologist who headed AstraZeneca's R&D centre in Montreal was given the dreadful task of announcing the lab's closing to his 130 fellow researchers.

"It was heartbreaking," he recalls. Mr. Walker, a Swiss national who moved to Canada in the mid-nineties, could have packed his bags and gone anywhere. But the thought never crossed his mind.

Mr. Walker chose Montreal as the Canadian site for a neuroscience lab specializing in treatments for chronic pain. He oversaw the construction of the research centre that opened in 1997. And in the past nine months, he has worked tirelessly to give the doomed lab a new lease on life.

Story continues below advertisement

"If big pharmaceutical companies are no longer going to conduct their early-stage research in-house, then we are going to be the ones selling it to them," says a fiery Mr. Walker.

Enter NéoMed, a new not-for-profit research organization whose mission is to bridge the gap between academic research and life science companies. Starting from the best projects put forward by universities and research centres, it will develop promising molecules to a stage where pharmaceutical companies would acquire them, explains Mr. Walker, NéoMed's chief scientific officer.

Unveiled yesterday, NéoMed is Quebec's new response to the disruptions in the life sciences industry that have knocked down Montreal's pharmaceutical sector.

The industry has been losing sleep. And it is not because it can get Viagra at cheap generic prices, as Pfizer's new ads proclaim, following a Supreme Court decision that shortened by two years the blue pill's protection from competition.

Big life science companies have been letting thousands of scientists go, as it is proving harder, and costlier, to discover drugs with wide commercial potential – so-called blockbusters. They now concentrate on late-stage research, which is less risky.

There are few places in Canada where the pain has been felt more acutely than in Montreal, which had attracted research centres over the years thanks to a generous drug reimbursement policy. One after the other, AstraZeneca, Sanofi-Aventis, Johnson & Johnson, Wyeth-Ayerst, Merck and Pfizer have announced lab closings and layoffs.

As a public-private partnership, NéoMed is rising from those ruins with a $71.5-million initial investment. AstraZeneca Canada donated its research facility in the Saint-Laurent suburb Technoparc and its equipment, as well as the intellectual property on three painkilling molecules the British-Swedish company was working on. It topped this estimated $35-million gift with $5-million in financing. Pfizer Canada also chipped in $3.5-million.

Story continues below advertisement

The Quebec government is offering an $8-million grant and a $20-million interest free loan that NéoMed should start to reimburse when its sales exceed $60-million.

The money is coming from a new $125-million five-year fund for research partnerships announced by the Parti Québécois government in Tuesday's budget.

The fund is one of the consolation prizes offered to the pharmaceutical industry for the cancellation of the province's overly generous drug reimbursement policy. Since this industrial policy had passed its expiry date, this is a wise decision the Liberals should have made earlier.

"We are adapting our policies to the new ways the pharmaceutical industry is conducting business," Finance Minister Nicolas Marceau said at a conference in NéoMed's lab.

This slant in favour of "open innovation" is inspired by a new generation of collaborative research labs. One such lab is the Centre for Drug Research and Development, headquartered at the University of British Columbia, in Vancouver.

The B.C. government just funnelled an additional $29-million on top of its initial $25-million grant to the institute. The CDRD has supported 135 research projects and advanced 80 technologies toward commercialization since it was launched in 2007.

Story continues below advertisement

Will such support fix Montreal's ailing industry? Mr. Walker says he is already in talks with 10 contract research organizations and other firms that could conduct R&D in the lab.

He also hopes to pursue the research on AstraZeneca's molecules. The different projects should give work to 120 researchers two years from now.

But many of the researchers laid off in the Montreal area have already moved away in search of interesting work, to Boston and other pharmaceutical hubs. And you have to wonder how promising AstraZeneca's molecules are if the multinational company is willing to give them away after reviewing its research portfolio.

But for Quebec's pharmaceutical industry, which has been battered by bad news, hope comes in small doses.

Report an error Licensing Options
About the Author
Chief Quebec correspondent

Sophie Cousineau is The Globe and Mail’s chief Quebec correspondent. She has been working as a journalist for more than 20 years, and was La Presse’s business columnist prior to joining the Globe in 2012. Ms. Cousineau earned a master’s degree in journalism from the University of Illinois and a bachelor’s degree in economics and political science from McGill University. More

Comments

The Globe invites you to share your views. Please stay on topic and be respectful to everyone. For more information on our commenting policies and how our community-based moderation works, please read our Community Guidelines and our Terms and Conditions.

We’ve made some technical updates to our commenting software. If you are experiencing any issues posting comments, simply log out and log back in.

Discussion loading… ✨

Combined Shape Created with Sketch.

Combined Shape Created with Sketch.

Thank you!

You are now subscribed to the newsletter at

You can unsubscribe from this newsletter or Globe promotions at any time by clicking the link at the bottom of the newsletter, or by emailing us at privacy@globeandmail.com.